Monday, 20 October 2025
  
Login

Australia's most trusted
source of pharma news

Monday, 20 October 2025
News

Broad funding... without Keytruda?

 Posted 20 October 2025 AM

After BMS' historic broad listing recommendation from the PBAC for its immunotherapy duo Opdivo and Yervoy in advanced and metastatic cancers, MSD will try again for multi-cancer funding for Keytruda.

The company received a "bewildering" knockback at the July meeting for its broad listing proposal firing off a no-holds barred response to the decision, telling the committee "it's simply not good enough".

To see the whole article, please login

Popular

Obesity pill heading to the TGA
Pharma sued over 'fake' Q&A
69 blockbusters face patent cliff
Broad funding... without Keytruda?
Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (2)

Sales & Customer Relations (13)

Clinical & Medical, R&D (5)

Regulatory, Pharmacovigilance & QA (1)

Other (11)

MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.


Subscribe
 
© 2003 - 2025 Lush Media | Privacy Statement | Subscribe to Pharma in Focus
home